Foundation Medicine, Inc. FMI
137.00 0.00 (+0.00%)
At closeJun 28, 2019, 6:07 PM EDT
137.00 Day range 137.00
136.75 52-week range 137.00
- EPS (ttm)
- -3.87
- P/E ratio
- -35.39
- Avg volume
- 347.22K
- Open
- 137.00
- Previous close
- 137.00
- Day's range
- 137.00 – 137.00
- 52-week range
- 136.75 – 137.00
- Earnings date
- Aug 7, 2018
No chart data for this range yet.
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Aug 7, 2018
Expected Aug 7, 2018. Consensus EPS estimate 0.00.
Financials — quick view
FMI Revenue — quarterly 57.01M
FMI Net income — quarterly -33.38M
FMI EPS — quarterly -0.90
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 7, 2018 | Jun 1, 2018 | -1.12 | — | — | — |
| May 2, 2018 | Mar 1, 2018 | -1.13 | — | — | — |
| Mar 7, 2018 | Dec 1, 2017 | -1.01 | — | — | — |
| Nov 1, 2017 | Sep 1, 2017 | -1.07 | — | — | — |
| Aug 1, 2017 | Jun 1, 2017 | -1.08 | — | — | — |
| May 9, 2017 | Mar 1, 2017 | -1.02 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 14, 2018 | Cowen & Co. | init | — | Outperform |
| Jan 28, 2018 | Goldman Sachs | init | — | Neutral |
| May 14, 2017 | BTIG Research | up | — | Buy |
| Mar 6, 2017 | Janney Capital | up | — | Neutral |
| Nov 2, 2016 | Benchmark | down | — | Hold |
| Aug 2, 2016 | Janney Capital | down | — | Sell |
News
Is Fastenal Co (FAST) Overvalued After Q3 Earnings Beat? EPS at $0.35 vs Estimated $0.34, Revenue at $2.463 Billion vs Estimated $2.440 Billion -- GF Score: 95/100 
Fastenal Co (FAST) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amid Pricing Challenges 
Spirit Announces Sale of Fiber Materials Inc. (FMI) to Tex Tech Industries 
Spirit Announces Purchase Agreement with Tex Tech Industries for Intended Sale of Fiber Materials, Inc. (FMI) 
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator 
Foundation Medicine Announces Timing for First Quarter 2018 Financial
Results and Conference Call 
Foundation Medicine Announces Timing for Fourth Quarter and Year-End
2017 Financial Results and Conference Call 
FDA Approves Foundation Medicine’s FoundationOne CDx™, the First and
Only Comprehensive Genomic Profiling Test for All Solid Tumors
Incorporating Multiple Companion Diagnostics 
66 Biggest Movers From Yesterday 
Foundation Medicine Announces Timing for Third Quarter 2017 Financial
Results and Conference Call
Your note
Sign in to keep a note on FMI — it syncs with the Stock Master app.